"We at the American Journal of Public Health have no interest in following the president's prohibitions on language." -- ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Good morning. We start in Washington, where just hours ago Donald Trump said the US would “take over” Gaza and that ...

From school meals to food labelling standards, contributors to our mini-series on Cayman's obesity crisis highlight a range ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Some people who use semaglutide (Ozempic, others) have noted sagging skin in the buttocks, calling it “Ozempic butt.” While lifestyle modifications may help prevent this weight loss side ...

A nationwide shortage of Ozempic is impacting the ability of people with diabetes to access the drug, especially in regional and remote Australia. The Therapeutic Goods Administration says there ...

Shamoon has joined the wave of people who are taking limited amounts not of psychedelics — to which the microdosing trend usually applies — but of the diabetes drug Ozempic (semaglutide), and ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

On the one hand, we see the rise of weight-loss drugs like Ozempic, hailed as a revolutionary aid for those who can afford it. Conversely, the body positivity movement encourages self-acceptance ...